News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cesca Therapeutics Management Provides Regulatory Update On Its Proposed U.S. Pivotal Critical Limb Ischemia Clinical Trial


7/8/2014 5:54:30 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RANCHO CORDOVA, Calif., July 8, 2014 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today that it recently participated in a pre-submission IDE (Investigational Device Exemption) teleconference with the Food and Drug Administration's ("FDA") Center for Biologics Evaluation and Research to discuss the Company's proposed pivotal clinical trial design for the treatment of Critical Limb Ischemia ("CLI") using its CLIRST (Critical Limb Ischemia Rapid Stem cell Therapy) treatment protocol delivered via the Company's proprietary SURGWERKS-CLI kit.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES